Back to results

TerminatedPhase 2

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

NCT02324491

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

+15 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2014-12
Enrollment: 152 participants
Sponsor: Zafgen, Inc.
Purpose: treatment

Locations (16)

Royal Prince Alfred HospitalCamperdown, New South Wales, Australia
Pendlebury ResearchCardiff, New South Wales, Australia
Australian Clinical Research NetworkMaroubra, New South Wales, Australia
Royal North Shore HospitalSt Leonards, New South Wales, Australia
Illawara Diabetes ServiceWollongong, New South Wales, Australia
Q-PharmHerston, Queensland, Australia
Ipswich Research InstituteIpswich, Queensland, Australia
AusTrialsSherwood, Queensland, Australia
CMAXAdelaide, South Australia, Australia
Box Hill HospitalBox Hill, Victoria, Australia
St. Vincent's HospitalFitzroy, Victoria, Australia
Barwon HealthGeelong, Victoria, Australia
Austin HealthHeidelberg West, Victoria, Australia
Emeritus ResearchMalvern East, Victoria, Australia
Baker IDI Heart and Diabetes InstituteMelbourne, Victoria, Australia
Keogh Institute for Medical ResearchNedlands, Western Australia, Australia

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus — TrialFind